Tissue-resident immune cells have long been appreciated for their ability to rapidly respond to pathogen signals and initiate both innate and adaptive immune responses. Such innate and adaptive tissue resident immune cells have also been shown to assimilate environmental cues, such as stress and injury, in their tissues of residence and coordinate cellular and molecular functions to maintain tissue homeostasis. Our growing appreciation for the role of the tissue-resident immune cells has also identified their dysfunction as a potentially contributing element to the loss of self-tolerance leading to autoimmunity or, reciprocally, the potential loss (or suppression) of ‘non-self’ surveillance allowing for tumor development. Pfizer scientists are interested in establishing collaborations with expert partners in the field of tissue resident immunity that would extend our knowledge of this growing area of science and impact our ability to therapeutically address aspects of disease pathogenesis and exacerbation that may be linked to tissue-resident immune cell processes.

Pfizer is exploring partnering opportunities to expand our understanding of tissue-resident immune cell biology and identify potential novel therapeutic interventions to modify human disease.

Specific areas of interest include:

  • Regulation of tissue-specific immune cell activation or function (e.g., ILC, NK/NKT, Treg, Trm)
  • Regulation of immune cell migration to and residency in select tissue (e.g., skin, gut, tumor, etc.)
  • Plasticity, phenotypic heterogeneity and responsiveness to tissue environment